VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NEO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NEONeoGenomics, Inc.
$15.25$2.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NEO
  4. Financial Ratios

NeoGenomics, Inc. (NEO) Financial Ratios

Latest Ratios: P/E Ratio -60.7x · EV/EBITDA 125.5x · ROE -12.4%. (2000–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NEO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.0B$1.5B$2.1B$2.0B$1.1B$4.1B$6.0B$3.0B$1.2B$704M$665M
Enterprise Value$2.3B$1.8B$2.3B$2.3B$1.5B$4.4B$6.0B$3.0B$1.3B$796M$758M
P/E Ratio →-60.71—————1443.43378.40437.85——
P/S Ratio2.492.073.163.432.258.4513.547.414.172.932.72
P/B Ratio2.341.802.312.161.153.698.675.973.603.423.56
P/FCF———————907.4137.89161.8947.67
P/OCF374.94288.04297.21———4122.60129.6925.7839.0230.94

P/E links to full P/E history page with 30-year chart

NEO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.503.523.892.939.0613.527.324.543.313.11
EV / EBITDA125.521042.48————276.5269.1039.5731.2429.41
EV / EBIT———————406.44125.22201.09351.82
EV / FCF———————895.3941.25183.1954.38

NEO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin38.8%38.8%43.9%41.3%36.9%38.6%41.8%48.1%46.0%42.4%45.2%
Operating Margin-9.1%-9.1%-13.9%-18.2%-30.9%-24.5%-3.1%3.2%3.6%1.2%1.1%
Net Profit Margin-14.9%-14.9%-11.9%-14.9%-28.3%-1.7%0.9%2.0%1.0%-0.2%-2.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-12.4%-12.4%-8.5%-9.1%-13.7%-0.9%0.7%1.9%1.0%-0.2%-2.9%
ROA-7.2%-7.2%-4.7%-5.1%-8.0%-0.6%0.5%1.3%0.6%-0.1%-1.7%
ROIC-4.3%-4.3%-5.9%-6.3%-8.6%-8.5%-1.8%2.2%2.1%0.8%0.7%
ROCE-5.1%-5.1%-6.3%-6.7%-9.2%-8.8%-1.8%2.4%2.7%1.0%0.9%

NEO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.560.560.670.650.610.550.310.260.350.510.57
Debt / EBITDA270.65270.65————10.043.073.534.144.12
Net Debt / Equity—0.370.260.290.350.27-0.02-0.080.320.450.50
Net Debt / EBITDA179.17179.17————-0.48-0.933.233.633.63
Debt / FCF———————-12.023.3621.306.72
Interest Coverage-28.38-28.38-11.19-13.06-20.02-0.83-1.001.981.610.710.22

NEO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.264.261.986.206.737.816.134.551.702.421.32
Quick Ratio3.943.941.895.956.467.545.734.321.562.211.21
Cash Ratio1.811.811.284.314.875.914.052.710.160.370.21
Asset Turnover—0.530.400.350.290.260.450.580.550.700.72
Inventory Turnover15.5715.5713.8514.3713.2612.718.7614.7217.2818.5021.38
Days Sales Outstanding—79.9183.1880.9885.7284.5087.7485.03101.4591.8083.01

NEO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield——————0.1%0.3%0.2%——
FCF Yield———————0.1%2.6%0.6%2.1%
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%4.3%0.0%8.3%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%4.3%0.0%8.3%
Shares Outstanding—$128M$127M$126M$124M$120M$112M$104M$92M$79M$78M

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent operating losses at scale

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Trailing Losses Versus Forward Earnings Gap

Based on reported figures, NEO trades at a negative trailing P/E of -4.01 but a forward P/E of 83.45 and forward EV/EBITDA of 7.38, a divergence that signals the market is pricing a recovery in earnings rather than rewarding current profitability.

The gap between trailing and forward multiples reflects that recent quarters have produced operating losses, so trailing metrics are not meaningful for pricing. The forward P/E of 83.45 implies investors are assuming substantial earnings expansion, which may be optimistic given that operating margin has only recently moved from -26.3% toward -3.8%. The P/B of 0.52 and P/S of 0.59 suggest the stock is priced below book and below sales, a level that may reflect skepticism about whether the goodwill-heavy asset base generates adequate returns.

Gross Margin Recovery Outpaces Operating Breakeven

As reported in financial statements, NEO's gross margin recovered from 39.8% in 2025Q4 to 46.2% in 2026Q3, while operating margin only improved to -3.8%, indicating that operating expenses still absorb nearly all incremental gross profit.

The improvement in gross margin is encouraging, but the persistent negative operating margin shows that SG&A and R&D growth has kept pace with gross profit gains. Net margin of -3.6% in 2026Q3 is close to operating margin, which suggests interest and other items are not the main drag, so the core issue is cost structure. Gross margin is the cleanest indicator of pricing and test mix trends here, while operating margin better reflects true earning power at this stage.

Negative Returns Narrowing but Not Yet Positive

Based on NEO's reported figures, ROIC moved from -3.2% in 2025Q2 to -0.5% in 2026Q3 and ROE from -5.2% to -1.0%, a trajectory toward breakeven returns that remains unproven over the ten-quarter window.

Both ROIC and ROE are improving, yet they remain negative, so the company is not yet earning its cost of capital on the large asset base. Goodwill of $524.0M inflates invested capital, which mechanically depresses returns and makes the improvement partly a function of acquisition accounting. Investors should monitor whether operating income turns durably positive, since returns on a goodwill-heavy base can only compound once earnings clear the capital charge.

Leverage Easing With Thin Interest Coverage

According to reported figures, NEO's debt-to-equity fell from 0.66 in 2024Q2 to 0.56 in 2026Q3 and total debt dropped to $449.1M, but interest coverage swings between positive and deeply negative values make debt service comfort difficult to assess.

The deleveraging trend is constructive, with debt reduced by roughly $157M over the period while equity remained above $800M. However, interest coverage is erratic because EBIT has been negative in most quarters, so the metric reflects operating losses rather than a stable debt service capacity. Debt-to-EBITDA values of 54 to 90 in recent quarters indicate that EBITDA is too small to support the debt load on a cash basis, which warrants further investigation into refinancing terms.

Strong Current Ratio Masks Shrinking Cash

Based on reported figures, NEO's current ratio of 3.53 in 2026Q3 appears comfortable, yet cash declined to $139.3M from $346.2M a year earlier, narrowing the actual liquidity buffer against $449.1M of total debt.

A current ratio above 3.5 looks robust, but it is driven largely by receivables and inventory rather than cash, and the quick ratio of 3.31 is only modestly lower, suggesting most current assets are not inventory-dependent. The sharp reduction in cash is the more relevant signal, since it shows that operating and investing outflows have consumed liquidity. Under a severe stress scenario, the position would depend on collecting receivables and sustaining cash generation, which the mixed cash flow record does not guarantee.

Misapplied Ratio: EV/EBITDA Distorted by Thin Earnings

The EV/EBITDA ratio is most commonly misapplied here, as NEO's reported EV/EBITDA of 427.14 on trailing figures obscures the earnings base, and forward multiples of 7.38 depend heavily on recovery assumptions investors should monitor.

Trailing EV/EBITDA becomes meaningless when EBITDA is near zero, so the reported 427 figure reflects a tiny denominator rather than a valuation level. Price-to-sales or forward EV/EBITDA, adjusted for stock-based compensation and acquisition amortization, would better convey what the market is paying for revenue and recovered earnings. Because roughly $16M to $18M of quarterly D&A and SBC are excluded from EBITDA add-backs, investors should test whether the forward multiple holds once these costs are treated as real expenses.

Download Financial Ratios Data

Includes 30+ ratios · 26 years · Updated daily

Consensus & Technical Research Suite
Open NEO Terminal

NEO Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NEO — Frequently Asked Questions

Quick answers to the most common questions about buying NEO stock.

What is NeoGenomics, Inc.'s P/E ratio?

NeoGenomics, Inc.'s current P/E ratio is -60.7x. The historical average is 29.9x.

What is NeoGenomics, Inc.'s EV/EBITDA?

NeoGenomics, Inc.'s current EV/EBITDA is 125.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.9x.

What is NeoGenomics, Inc.'s ROE?

NeoGenomics, Inc.'s return on equity (ROE) is -12.4%. The historical average is -39.4%.

Is NEO stock overvalued?

Based on historical data, NeoGenomics, Inc. is trading at a P/E of -60.7x. Compare with industry peers and growth rates for a complete picture.

What are NeoGenomics, Inc.'s profit margins?

NeoGenomics, Inc. has 38.8% gross margin and -9.1% operating margin.

How much debt does NeoGenomics, Inc. have?

NeoGenomics, Inc.'s Debt/EBITDA ratio is 270.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.